News |  Disclaimer |  Contact |  Sitemap |  Privacy Notice | 
About us  |   Business Development  |   Territories  |   Partners  |  
Ewopharma introduces a new therapy for late-stage Parkinson patients

A new therapy for late-stage Parkinson patients, who cannot be effectively treated using oral anti-Parkinson medicine, is introduced by Ewopharma. Dacepton (apomorphine hydrochloride) is used to treat movement disorders (“on-off” phenomena). Apomorphine is the strongest clinically available dopamine agonist and its effects unfold through direct stimulation of dopamine receptors in the central nervous system.

Dacepton offers a subcutaneous continuous infusion using a mini-pump and has significant advantages over the two alternative treatments (Duodopa and Deep Brain Stimulation), which both require surgical intervention. Ewopharma has set up a cycle of care for Parkinson patients and the first patients for a state sponsored drug program are currently being enrolled in Bulgaria.

Dacepton is a product from EVER Neuro Pharma; an independent Austrian company focusing on neurology and critical care.